Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tessera Inc.

Latest From Tessera Inc.

Start-Up Previews (6/02)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Gene Delivery, features profiles of ImaRx Therapeutics Inc., Intradigm Corp., Protiva Biotherapeutics Inc. and Tranzyme Inc. Plus these Selected Start-Ups across Health Care: FASgen Inc., Power Medical Interventions Inc., NephRx Corp. and Tessera Diagnostics Inc.

Tessera Diagnostics Inc.

Tessera Diagnostics, founded in December 2000, is focusing on developing a group of protein markers for early detection of cancer. It's first indication is prostate cancer, and it has in-licensed a group of 14 markers from a family of proteins called NMPs for early detection of the disease. It believes some of these markers are specific and highly sensitive to the disease, and as a group they will provide better information than any test currently available.
Medical Device Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Tessera Diagnostics Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Tessera Inc.
  • Senior Management
  • H. Raymond Cairncross, CEO
    John Brenneman, CFO
    Dan Clemens, VP, R&D
    Michael C Perry, SVP, Sales & Mktg.
  • Contact Info
  • Tessera Inc.
    Phone: (206) 223-2714
    119 1st Ave. South
    Ste. 410
    Seattle , WA 98104